Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ardea Biosciences, Inc.
Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, its Lead MEK Inhibitor, in Combination with Nexavar sorafenib in Patients with Advanced Cancer
November 4th, 2008
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced that it has initiated a Phase 1/2 study of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, in combination with Nexavar, which is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anti-cancer agents, including sorafenib. This Phase 1/2 study in patients with advanced cancer will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of...
Source: Cancer Weekly (2008-11-04)
|
